Determination of irinotecan, <scp>SN</scp>‐38 and <scp>SN</scp>‐38 glucuronide using <scp>HPLC</scp>/<scp>MS</scp>/<scp>MS</scp>: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients

Chalirmporn Atasilp, Phichai Chansriwong, Ekapob Sirachainan, Thanyanan Reungwetwattana, Apichaya Puangpetch, Santirhat Prommas, Suwannee Sirilerttrakul, Budsaba Rerkarmnuaychoke, Sansanee Wongwaisayawan, Chonlaphat Sukasem

Journal of Clinical Laboratory Analysis · 2017 · 21 citations · 12 references

DOIFull text

Open access

Concepts

Abstract

BACKGROUND: Irinotecan (CPT-11) is chemotherapy used mainly in the metastatic colorectal cancer. The purpose of this study was to develop and validate the LC-MS/MS for the simultaneous determination of CPT-11, SN-38, and SN-38G. METHODS: A 100 μL of plasma was prepared after protein precipitation and analyzed on a C18 column using 0.1% acetic acid in water and 0.1% acetic acid in acetonitrile as mobile phases. The mass spectrometer worked with multiple reaction monitoring (MRM) in positive scan mode. The standard curves were linear on a concentration range of 5-10 000 ng/mL for CPT-11, 5-1000 ng/mL for SN-38, and 8-1000 ng/mL for SN-38G. RESULTS: In this assay, the intra and interday precision consisted of ≤9.11% and ≤11.29% for CPT-11, ≤8.70% and 8.31% for SN-38, and ≤9.90 and 9.64% for SN-38G. CONCLUSION: This method was successfully used to quantify CPT-11, SN-38, and SN-38G and applied to a pharmacokinetic study.

References

12